PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
 
BMC Cancer. 2010; 10: 147.
Published online 2010 April 18. doi:  10.1186/1471-2407-10-147
PMCID: PMC2861659

Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population

Abstract

Background

The tumor suppressor TP53 and its negative regulator MDM2 play crucial roles in carcinogenesis. Previous case-control studies also revealed TP53 72Arg>Pro and MDM2 309T>G polymorphisms contribute to the risk of common cancers. However, the relationship between these two functional polymorphisms and nasopharyngeal carcinoma (NPC) susceptibility has not been explored.

Methods

In this study, we performed a case-control study between 522 NPC patients and 722 healthy controls in a Chinese population by using PCR-RFLP.

Results

We found an increased NPC risk associated with the MDM2 GG (odds ratio [OR] = 2.83, 95% confidence interval [CI] = 2.08-3.96) and TG (OR = 1.49, 95% CI = 1.16-2.06) genotypes. An increased risk was also associated with the TP53 Pro/Pro genotype (OR = 2.22, 95% CI = 1.58-3.10) compared to the Arg/Arg genotype. The gene-gene interaction of MDM2 and TP53 polymorphisms increased adult NPC risk in a more than multiplicative manner (OR for the presence of both MDM2 GG and TP53 Pro/Pro genotypes = 7.75, 95% CI = 3.53-17.58).

Conclusion

The findings suggest that polymorphisms of MDM2 and TP53 genes may be genetic modifier for developing NPC.

Background

As an important tumor suppressor, TP53 protein level is low or undetectable in normal cells, but diverse forms of stress may trigger its production, resulting in either cell cycle arrest or apoptotic cell death [1,2]. High frequencies of TP53 mutation and/or deletion are found in a wide variety of human malignancies, including nasopharyngeal carcinoma (NPC), which is believed to be contributed to tumorigenesis and progression [3-5].

Recently, Bond et al. reported that a T>G polymorphism at position 309 downstream from MDM2 intron 1 disrupts an Sp1 regulatory element and the T allele thus has a strikingly lower promoter activity compared with the G allele [6]. Moreover, a single nucleotide polymorphism has been identified in the coding region of TP53, which causes an Arg72>Pro amino acid substitution [7]. It has been shown that, compared with Pro allele, the Arg allele is faster to induce apoptosis and more efficient in suppressing transformation. Many molecular epidemiologic data found that these two polymorphisms are likely candidate genetic markers of certain cancers [8-10]. However, the gene-gene interaction of these two polymorphisms in MDM2 and TP53 has not been examined in NPC studies to date. Because of their significant impact in several tumors, these two polymorphisms might also affect the function of MDM2 and TP53 and play an important role in NPC development. These two polymorphisms might impact individual susceptibility to carcinogenesis. Based on this hypothesis, we carried out a hospital-based case-control study to investigate the relationship between polymorphisms in MDM2 309T>G and TP53 Arg72Pro and the risk of NPC in Chinese population.

Methods

Study Subjects

This study included 522 NPC patients and 712 healthy population controls. All subjects were ethnically homogenous Han Chinese. Patients with newly diagnosed NPC were consecutively recruited from March 2001 to May 2007, at the Sir Run Run Shaw Hospital, Zhejiang University (Hangzhou) and Zhejiang Cancer Hospital (Hangzhou). All eligible patients diagnosed at the hospital during the study period were recruited, with a response rate of 94%. Patients were from Hangzhou city and its surrounding regions and there were no age, stage, and histology restrictions. The tumor, node, metastasis (TNM) classification and tumor staging was evaluated according to the 2002 American Joint Committee on Cancer staging system [11]. The clinical features of the patients are summarized in Table Table1.1. Population controls were cancer-free people living in Hangzhou region; they were selected from a nutritional survey conducted in the same period as the cases were collected. The control subjects were randomly selected from a database consisting of 2500 individuals based on a physical examination. The selection criteria included no history of cancer and frequency matched to cases on age and sex. Median age was 46 years (range 26-81) for case patients and 47 years (range 22-85) for control subjects (P = 0.78). At recruitment, informed consent was obtained from each subject. This study was approved by the Medical Ethics Committee of Sir Run Run Shaw Hospital and Zhejiang Cancer Hospital.

Table 1
Distribution of selected characteristics by case-control status in NPC association analysis.

Polymorphism analysis

Genomic DNA was isolated from the peripheral blood lymphocytes of the study subjects. Genotypes were analyzed using PCR-based methods as described below. Genotyping was performed without knowledge of subjects' case/control status. A 30% masked, random sample of cases and controls was tested twice by different persons and the results were concordant for all masked duplicate sets.

The genotypes of TP53 Arg72Pro (rs1042522, G>C) were analyzed by PCR-RFLP method on the basis of that reported previously [12]. The primers used were TP53 F, 5'-TTG CCG TCC CAA GCA ATG GAT GA-3' and TP53 R, 5'-TCT GGG AAG GGA CAG AAG ATG AC-3', which produce a 199-bp fragment containing the G/C site. Amplification was accomplished with a 25 μl reaction mixture containing ~100 ng template DNA, 0.5 μM each primer, 0.2 mM each dNTP, 1.5 mM MgCl2, and 1.2 units of Taq DNA polymerase with 1 × Reaction buffer (Promega, Madison, WI, USA). PCR profile consisted of an initial melting step of 2 min at 94°C, followed by 35 cycles of 30 s at 94°C, 30 s at 56°C, and 30 s at 72°C, and a final elongation step of 7 min at 72°C. The 199-bp PCR products were then subject to the digestion with BstUI (New England Biolabs, UK) and separated on a 3.0% agarose gel. The genotypes identified by BstUI digestion were confirmed by DNA sequencing (Figure (Figure11).

Figure 1
Representative PCR-RFLP for different genotypes containing the TP53 Arg72Pro polymorphism site and DNA sequencing analysis. (A) M: DNA size markers; lane 1, 2, 4 and 5: TP53 72Pro/Pro; lane 6, 7 and 8: TP53 72Arg/Pro; lane 3: TP53 72Arg/Arg. (B) The PCR ...

MDM2 SNP309 (rs2279744, T>G) genotypes were analyzed using the tetra-primer amplification refractory mutation system (ARMS)-PCR method [13]. The primers for ARMS-PCR amplification of DNA fragment containing the MDM2 SNP309 T allele were MDM2 F1: 5'-GGG GGC CGG GGG CTG CGG GGC CGT TT-3' and MDM2 R1: 5'-TGC CCA CTG AAC CGG CCC AAT CCC GCC CAG-3'; For the MDM2 SNP309 G allele they were MDM2 F2: 5'-GGC AGT CGC CGC CAG GGA GGA GGG CGG-3' and MDM2 R2: 5'-ACC TGC GAT CAT CCG GAC CTC CCG CGC TGC-3'. The amplification was accomplished with a 10-μl reaction mixture containing 10 ng of template DNA, 0.8 μM of primers MDM2 F1 and MDM2 R1, 4.8 μM of primers MDM2 F2 and MDM2 R2, 0.2 mM of dNTPs, 1.5 mM of MgCl2, and 0.4 U of HotStar TaqTM with 1 × buffer and 1 × Q-solution (Qiagen, Chatsworth, CA). The reaction was carried out with an initial melting step of 15 min at 95°C, followed by 35 cycles of 45 sec at 95°C, 45 sec at 64°C, and 1 min at 72°C, and a final elongation step of 7 min at 72°C. The amplified DNA was visualized on agarose gel containing ethidium bromide. The MDM2 SNP309 T allele generated a 122-bp band, and the G allele generated a 158-bp band. They had a common 224-bp band, which was amplified by primers MDM2 F2 and MDM2 R1. The genotypes identified by PCR-RFLP and ARMS-PCR digestion were confirmed by DNA sequencing (Figure (Figure22).

Figure 2
Representative tetraprime ARMS-PCR for different genotypes containing the MDM2 SNP309 T>G polymorphism site and DNA sequencing analysis. (A) M: DNA size markers; lane 1, and 9: MDM2 309TT; lane 2, 3, 4, 6 and 8: MDM2 309TG; lane 5 and 7: MDM2 ...

Real-time analysis of MDM2 mRNA

Total RNA was isolated from Seventy-one NPC tissues using the Trizol reagent (Molecular Research Center, Inc., Cincinnati, OH) and converted to cDNA using an oligo (dT)15 primer and Superscript II (Invitrogen, Carlsbad, CA). Relative gene expression quantitation for MDM2, with β-actin as an internal reference gene, was carried out using ABI Prism 7300 sequence detection system (Applied Biosystem, Foster City, CA) in triplicates, based on the SYBR-Green method [8]. The primers used for MDM2 were 5'-TGT AAG TGA ACA TTC AGG TG-3' and 5'-TTC CAA TAG TCA GCT AAG GA-3'; and for β-actin were 5'-GGC GGC ACC ACC ATG TAC CCT-3' and 5'-AGG GGC CGG ACT CGT CAT ACT-3'. The PCR reaction mixture consisted of 0.1 μmol/L of each primer, 1 × SYBR Premix EX Taq (Perfect Real Time) premix reagent (TaKaRa, Dalian, China), and 50 ng cDNA to a final volume of 20 μL. Cycling conditions were 95°C for 10 minutes, followed by 40 cycles at 95°C of 15 seconds and 62°C for 1 minute. PCR specificity was confirmed by dissociation curve analysis and gel electrophoresis. All analysis were done in a blinded fashion with the laboratory persons unaware of genotyping data. The expression of individual MDM2 measurements was calculated relative to expression of β-actin using a modification of the method described by Lehmann et al [14].

Statistical Analysis

χ2 tests were used to examine the differences in the distributions of genotypes between cases and controls. The association between the TP53 and MDM2 polymorphisms and risk of NPC were estimated by ORs and their 95% CIs, which were calculated by unconditional logistic regression models. We tested the null hypotheses of multiplicative gene-gene interactions by evaluated departures from multiplicative joint effect models by including main effect variables and their product terms in the logistic regression model [15]. A more-than-additive interaction was suggested when OR11 > OR10 + OR01 -1, for which OR11 = OR when both factors were present, OR10 = OR when only factor 1 was present and OR01 = OR when only factor 2 was present. A more-than-multiplicative interaction was suggested when OR11 >OR10 ×OR01. The correlation of genotypes and clinical parameters was analyzed via the Fisher's exact test or χ2 test as appropriate. The normalized expression values of MDM2 were compared by Kruskal-Wallis one way ANOVA. All P-values were two-sided with a P-value < 0.05 considered to be statistically significant. All analysis was carried out with Statistical Analysis System software (Version 9.0; SAS Institute, Cary, NC, USA).

Results

Allele and Genotype Distribution

The genotype results are shown in Table Table2.2. The allele frequencies for MDM2 G and TP53 Pro were 0.423 and 0.426 in controls, and 0.555 and 0.518 in cases respectively. The observed genotype frequencies of MDM2 and TP53 polymorphisms in both controls and cases did not deviated from those expected from the Hardy-Weinberg equilibrium. Distributions of these MDM2 and TP53 genotype were then compared among cases and controls. The frequencies of MDM2 TT, TG and GG genotypes among patients were significantly different compared to controls (Ptrend < 0.001), with the GG homozygotes being significantly overrepresented among patients compared to controls (P < 0.001). Moreover, Logistic regression analysis showed that subjects with TP53 Pro allele significant increased risk of NPC compared with subjects carrying the Arg allele (OR for the Arg/Pro genotype, 1.43; 95%CI, 1.22-2.13; OR for the Pro/Pro genotype, 2.22; 95%CI, 1.58-3.10; Ptrend < 0.001), suggesting that the Pro allele is the high-risk allele.

Table 2
Genotype and allele frequencies of TP53 and MDM2 among cases and controls and their association with the risk of NPC.

The effects of the TP53 and MDM2 polymorphisms were additionally examined with stratification by age, tumor size, metastatic status and Epstein-Barr virus (EBV) infection status. However, no significant association was observed between age and the TNM stage at the time of NPC diagnosis and the polymorphism of this gene, and no interaction was detected between the polymorphism and status of EB virus infection (data not shown).

Gene-Gene Interaction between MDM2 and TP53 Polymorphisms

We examined whether there was a statistical interaction between the MDM2 and TP53 polymorphisms (Table (Table3).3). The data showed that patients who carried the MDM2 GG genotype were also more likely to carry the TP53 Pro/Pro genotype than the controls (10.3% vs. 2.8%, P < 0.001). The presence of one MDM2 GG genotype, but not one TP53 Pro/Pro genotype, were associated with an increased risk of NPC (OR = 2.83, 95% CI = 1.33-5.90), compared to the lack of such a genotype. However, the presence of both MDM2 GG and TP53 Pro/Pro genotypes was associated with an even higher risk for NPC increase (OR = 7.75, 95% CI = 3.53-17.58; P < 0.05, test for homogeneity) compared to those who lacked both genotypes. These results clearly indicate a more than multiplicative interaction [15] between the MDM2 GG and TP53 Pro/Pro genotype in the risk of developing NPC.

Table 3
Risk of NPC associated with MDM2 genotypes by TP53 genotypes.

MDM2 RNA Levels in NPC tissues from Different Genotype Carriers

To examine the effect of the MDM2 309T>G polymorphism on MDM2 expression in the target tissues, the levels of MDM2 mRNA in individual NPC tissues were quantified by real-time PCR (Figure (Figure3).3). The results showed that the MDM2 GG genotype carriers (n = 19) had significantly higher MDM2 mRNA level than the MDM2 TT genotype carriers [0.050 ± 0.033 (n = 19) versus 0.014 ± 0.009 (n = 18), P < 0.001]. However, the MDM2 TG genotype carriers (n = 34) had a MDM2 mRNA level that was very similar to that of the TT genotype carriers (0.015 ± 0.013 versus 0.014 ± 0.009, P = 0.610).

Figure 3
MDM2 mRNA expression level in NPC tissue as function of MDM2 genotype. Columns, mean; bars, ± SD normalized to β-actin. Expression level among the GG genotype was significantly different from that among the GT or TT genotype (P < ...

Discussion

In the present study, our group found that MDM2 and TP53 polymorphisms may influence the development of NPC in a Chinese population. On the basis of examining 522 cases and 712 controls, our data showed that MDM2 309GG, which increase MDM2 expression level in NPC tissue, and TP53 72Pro/Pro genotypes were statistically significantly associated with increased risk of NPC. In addition, the association between these two polymorphisms and the risk of NPC displayed a multiplicative gene-gene interaction, which rendered the subjects carrying both MDM2 309GG and TP53 72Pro/Pro genotypes at much higher risk for developing NPC.

Our results showing an association between risk of NPC and polymorphisms of MDM2 and TP53 are biologically plausible for the following reasons. Firstly, there is broad evidence suggesting that TP53 is a key gene in maintaining genomic integrity and preventing tumorigenesis [16-19]. The association between mutation of TP53 and susceptibility to tumor formations has been tested in several studies with genetically modified animals. It was found that mice lacking the inactivating mutation in one tp53 allele developed fewer tumors than mice harboring it and they developed tumors very early in life and at very high frequencies [20]. Moreover, overexpression of MDM2, which can led to loss of TP53 activity, was also observed in a variety of tumors with diverse tissue origins [21,22]. Secondly, the investigated polymorphisms in the TP53 and MDM2 genes have functional consequences [6,7,23]. Our real-time PCR finding is consistent with recent reports by Bond et al. and Hong et al [6,8] that the MDM2 309GG genotype carriers had significantly higher MDM2 expression in NPC tissues than the TT and TG genotype carriers, suggesting the variant MDM2 genotype may cause attenuated TP53 function.

Several case-control studies have examined the association between these two polymorphisms and many tumor types, but the results are conflicting [8,9,24-27]. A meta-analysis of 21 studies showed that ORs of a variety of cancers associated with the MDM2 GG and TG genotype were 1.17 (95% CI = 1.04-1.33) and 1.15 (95% CI = 1.03-1.28), respectively [28]. Moreover, another meta-analysis study reported that the TP53 Pro/Pro polymorphisms was significantly increase susceptibility to NPC [29]. Phang et al. reported in a study conducted in Singapore Chinese that the MDM2 309SNP was not associated with leukemia [30]. However, Xiong et al. also found an increased risk of acute myeloid leukemia (AML) associated with MDM2 309GG genotype [9]. Zhou et al. shown that MDM2 309SNP may be a risk factor for occurrence of NPC [31]. Moreover, the control frequencies of TP53 Arg72Pro and MDM2 SNP309 in our present study were similar with Asian population in published papers [28,29]. Our study provided strong molecular epidemiologic evidence to support the hypothesis that TP53 72Arg/Pro and MDM2 309T>G polymorphisms also affect the development of NPC.

Although it is generally believed that TP53 pathway also plays a critical role in tumor aggressive course [32,33], we did not find significant correlations between TP53 and MDM2 genotypes and the prognosis status of NPC in the present study. These results suggest that the examined polymorphisms in TP53 and MDM2 might not serve as a sole risk marker of prognosis. Further examinations of larger patient series with prospectively follow-up clinical outcomes especially the survival rates may be required. Moreover, our study may have certain limitations because of the study design. Selection bias and/or systematic error may occur because the cases were from the hospital and the controls were from the community. Some factors which may interact with genotype or act as potential confounders in analysis such as information of nutrition is not available in our case-control study.

Conclusion

The current study demonstrated a significant association between the TP53 72Arg/Pro and MDM2 309T>G polymorphisms and the risk of developing NPC for the first time. The association of MDM2 polymorphism with the risk of NPC displayed a multiplicative gene-gene interaction with the TP53 72Arg/Pro polymorphism. These molecular epidemiology findings are consistent with the results obtained from the functional analysis. Because MDM2 overexpression and high frequencies of TP53 mutation are found in many tumor types, additional studies on other tumor types would be warranted. Moreover, the possible role of these polymorphisms in disease prognosis should also be addressed in the future studies.

Abbreviations

MDM2: mouse double minute 2; CI: confidence interval; OR: odds ratio; NPC: nasopharyngeal carcinoma; SNP: single nucleotide polymorphism.

Conflicts of interest statement

The authors declare that they have no competing interests.

Authors' contributions

MX participated in molecular genetic studies and drafted the manuscript. LZ carried out bioinformatics analysis and critically revised the manuscript. XZ performed the genotyping and statistical analysis and participated in the critical revision of the manuscript. JH, HJ and SH participated in collection of data and manuscript preparation. YL conceived of the study, and participated in its design and coordination. All authors read and approved the final manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/10/147/prepub

Acknowledgements

Our work was supported by grant 0440065 from Jiangxi Provincial Natural Science Foundation of China.

References

  • Kruse JP, Gu W. Modes of p53 regulation. Cell. 2009;137:609–622. doi: 10.1016/j.cell.2009.04.050. [PubMed] [Cross Ref]
  • Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2:594–604. doi: 10.1038/nrc864. [PubMed] [Cross Ref]
  • Golubovskaya VM, Conway-Dorsey K, Edmiston SN, Tse CK, Lark AA, Livasy CA, Moore D, Millikan RC, Cance WG. FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer. 2009;125:1735–1738. doi: 10.1002/ijc.24486. [PMC free article] [PubMed] [Cross Ref]
  • Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002;19:607–614. doi: 10.1002/humu.10081. [PubMed] [Cross Ref]
  • Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Hirai H, Ishikawa F, Takaku F. Mutations of the p53 gene in lymphoid leukemia. Blood. 1991;77:1153–1156. [PubMed]
  • Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602. doi: 10.1016/j.cell.2004.11.022. [PubMed] [Cross Ref]
  • Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–365. doi: 10.1038/ng1093. [PubMed] [Cross Ref]
  • Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, Tan W, Liu Z, Lin D. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res. 2005;65:9582–9587. doi: 10.1158/0008-5472.CAN-05-1460. [PubMed] [Cross Ref]
  • Xiong X, Wang M, Wang L, Liu J, Zhao X, Tian Z, Wang J. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res. 2009;33:1454–1458. doi: 10.1016/j.leukres.2009.04.007. [PubMed] [Cross Ref]
  • Chen X, Sturgis EM, El-Naggar AK, Wei Q, Li G. Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. Carcinogenesis. 2008;29:2120–2125. doi: 10.1093/carcin/bgn191. [PMC free article] [PubMed] [Cross Ref]
  • Greene FL, Page DL, Fleming ID, Haller DG, Morrow M. AJCC Cancer Staging Manual. New York: Springer - Verlag; 2002. p. 6.
  • Ara S, Lee PS, Hansen MF, Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res. 1990;18:4961. doi: 10.1093/nar/18.16.4961. [PMC free article] [PubMed] [Cross Ref]
  • Ye S, Dhillon S, Ke X, Collins AR, Day IN. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 2001;29:E88–8. doi: 10.1093/nar/29.17.e88. [PMC free article] [PubMed] [Cross Ref]
  • Lehmann U, Kreipe H. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods. 2001;25:409–418. doi: 10.1006/meth.2001.1263. [PubMed] [Cross Ref]
  • Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis. 2002;23:381–387. doi: 10.1093/carcin/23.3.381. [PubMed] [Cross Ref]
  • Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233–1238. doi: 10.1126/science.1978757. [PubMed] [Cross Ref]
  • Malkin D. p53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet. 1993;66:83–92. doi: 10.1016/0165-4608(93)90233-C. [PubMed] [Cross Ref]
  • Runnebaum IB, Tong XW, Moebus V, Heilmann V, Kieback DG, Kreienberg R. Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines. Hum Genet. 1994;93:620–624. doi: 10.1007/BF00201559. [PubMed] [Cross Ref]
  • Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G, Marcel V, Aguiar E, Giacomazzi J, Ewald IP, Giugliani R, Hainaut P, Ashton-Prolla P. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett. 2008;261:21–25. doi: 10.1016/j.canlet.2007.10.044. [PubMed] [Cross Ref]
  • Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215–221. doi: 10.1038/356215a0. [PubMed] [Cross Ref]
  • Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res. 1999;59:1–7. [PubMed]
  • Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26:3453–3459. doi: 10.1093/nar/26.15.3453. [PMC free article] [PubMed] [Cross Ref]
  • Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092–1100. [PMC free article] [PubMed]
  • Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, Wang Y, Lin D. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat. 2006;27:110–117. doi: 10.1002/humu.20277. [PubMed] [Cross Ref]
  • Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T, Zhao D, Yu D, Liu J, Lin D. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis. 2007;28:1996–2001. doi: 10.1093/carcin/bgm168. [PubMed] [Cross Ref]
  • Bittenbring J, Parisot F, Wabo A, Mueller M, Kerschenmeyer L, Kreuz M, Truemper L, Landt O, Menzel A, Pfreundschuh M, Roemer K. MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians. BMC Cancer. 2008;8:116. doi: 10.1186/1471-2407-8-116. [PMC free article] [PubMed] [Cross Ref]
  • Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A, Eigenberger K, Greil R, Tinhofer I. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol. 2008;26:2252–2257. doi: 10.1200/JCO.2007.11.5212. [PubMed] [Cross Ref]
  • Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev. 2007;16:2717–2723. doi: 10.1158/1055-9965.EPI-07-0634. [PubMed] [Cross Ref]
  • Zhuo XL, Cai L, Xiang ZL, Zhuo WL, Wang Y, Zhang XY. TP53 codon 72 polymorphism contributes to nasopharyngeal cancer susceptibility: a meta-analysis. Arch Med Res. 2009;40:299–305. doi: 10.1016/j.arcmed.2009.03.006. [PubMed] [Cross Ref]
  • Phang BH, Linn YC, Li H, Sabapathy K. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer. 2008;44:760–766. doi: 10.1016/j.ejca.2008.02.007. [PubMed] [Cross Ref]
  • Zhou G, Zhai Y, Cui Y, Zhang X, Dong X, Yang H, He Y, Yao K, Zhang H, Zhi L, Yuan X, Qiu W, Zhang X, Shen Y, Qiang B, He F. MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin Cancer Res. 2007;13:2627–2633. doi: 10.1158/1078-0432.CCR-06-2281. [PubMed] [Cross Ref]
  • Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85:1580–1589. [PubMed]
  • Nayak MS, Yang JM, Hait WN. Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res. 2007;67:5831–5839. doi: 10.1158/0008-5472.CAN-06-4533. [PubMed] [Cross Ref]

Articles from BMC Cancer are provided here courtesy of BioMed Central